You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemsirolimus
Accession NumberDB06287
TypeSmall Molecule
GroupsApproved
DescriptionTemsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
Structure
Thumb
Synonyms
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
Torisel
External Identifiers
  • CCI-779
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-temsirolimusSolution25 mgIntravenousGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
ToriselLiquid25 mgIntravenousPfizer Canada Inc2008-01-11Not applicableCanada
ToriselInjection, solution, concentrate30 mgIntravenousPfizer Limited2007-11-19Not applicableEu
ToriselKitWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2007-07-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII624KN6GM2T
CAS number162635-04-3
WeightAverage: 1030.2871
Monoisotopic: 1029.602485741
Chemical FormulaC56H87NO16
InChI KeyCBPNZQVSJQDFBE-FUXHJELOSA-N
InChI
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
IUPAC Name
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
SMILES
OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[[email protected]](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[[email protected]](C)C[[email protected]](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[[email protected]]3C(=O)O2)C[[email protected]]1OC
Pharmacology
IndicationFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionTemsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Serine/threonine-protein kinase mTORProteinyes
inhibitor
HumanP42345 details
Related Articles
AbsorptionInfused intravenous over 30 - 60 minutes. Cmax is typically observed at the end of infusion
Volume of distribution

172 L in whole blood of cancer patients; both temsirolimus and sirolimus are extensive distributed partitioned into formed blood elements

Protein binding87% bound to plasma proteins in vitro at a concentration of 100 ng/ml
Metabolism

Primarily metabolized by cytochrome P450 3A4 in the human liver. Sirolimus, an equally potent metabolite, is the primary metabolite in humans following IV infusion. Other metabolic pathways observed in in vitro temsirolimus metabolism studies include hydroxylation, reduction and demethylation.

SubstrateEnzymesProduct
Temsirolimus
Not Available
SirolimusDetails
Route of eliminationExcreted predominantly in feces (76%), 4.6% of drug and metabolites recovered in urine. 17% of drug was not recovered by either route following a 14-day sample collection.
Half lifeTemsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.
Clearance

16.2 L/h (22%)

ToxicityTemsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of temsirolimus greater than 25 mg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.Experimental
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Temsirolimus.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Temsirolimus.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Temsirolimus.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Temsirolimus.Approved
AcetaminophenThe serum concentration of Temsirolimus can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Temsirolimus.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Temsirolimus.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Temsirolimus.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Temsirolimus.Experimental
AlbendazoleThe serum concentration of Temsirolimus can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Temsirolimus can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Temsirolimus can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Temsirolimus.Approved, Investigational
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temsirolimus.Approved
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Temsirolimus.Approved
ALT-110The risk or severity of adverse effects can be increased when Temsirolimus is combined with ALT-110.Investigational
AmantadineThe serum concentration of Temsirolimus can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Temsirolimus.Approved, Investigational
Aminohippuric acidThe serum concentration of Temsirolimus can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Temsirolimus can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Temsirolimus can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Temsirolimus can be increased when it is combined with Amlodipine.Approved
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Temsirolimus.Approved
AmsacrineThe serum concentration of Temsirolimus can be increased when it is combined with Amsacrine.Approved
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Temsirolimus.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Temsirolimus.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.Approved
AprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Temsirolimus.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Temsirolimus.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Temsirolimus.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Temsirolimus.Approved, Investigational
AstemizoleThe serum concentration of Temsirolimus can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Temsirolimus.Approved, Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Temsirolimus.Approved, Investigational
AtenololThe serum concentration of Temsirolimus can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Temsirolimus can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Temsirolimus.Approved, Investigational
AzelastineThe serum concentration of Temsirolimus can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Temsirolimus can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Temsirolimus.Investigational
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Temsirolimus.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Temsirolimus.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Temsirolimus.Approved, Investigational
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Temsirolimus.Experimental
BenzocaineThe serum concentration of Temsirolimus can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Temsirolimus can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
BexaroteneThe serum concentration of Temsirolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The risk or severity of adverse effects can be increased when Bi201335 is combined with Temsirolimus.Investigational
BiperidenThe serum concentration of Temsirolimus can be increased when it is combined with Biperiden.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Temsirolimus.Approved
BortezomibThe metabolism of Temsirolimus can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Temsirolimus can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Temsirolimus.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.Approved
BromocriptineThe serum concentration of Temsirolimus can be increased when it is combined with Bromocriptine.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Temsirolimus.Withdrawn
BuprenorphineThe serum concentration of Temsirolimus can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Temsirolimus can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temsirolimus.Approved
CaffeineThe serum concentration of Temsirolimus can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Temsirolimus.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Temsirolimus.Approved
CandesartanThe serum concentration of Temsirolimus can be increased when it is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Temsirolimus.Experimental
CandoxatrilatThe risk or severity of adverse effects can be increased when Candoxatrilat is combined with Temsirolimus.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Temsirolimus.Approved
CarbamazepineThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Temsirolimus.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Temsirolimus.Approved
CarvedilolThe serum concentration of Temsirolimus can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Temsirolimus can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Temsirolimus.Experimental
CDX-110The risk or severity of adverse effects can be increased when Temsirolimus is combined with CDX-110.Investigational
CeritinibThe serum concentration of Temsirolimus can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Temsirolimus.Withdrawn
ChloroquineThe serum concentration of Temsirolimus can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Temsirolimus can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Temsirolimus can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Temsirolimus can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Temsirolimus.Experimental
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Temsirolimus.Experimental
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Temsirolimus.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Temsirolimus.Approved
CimetidineThe serum concentration of Temsirolimus can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Temsirolimus.Approved
CitalopramThe serum concentration of Temsirolimus can be increased when it is combined with Citalopram.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Temsirolimus.Approved
ClemastineThe metabolism of Temsirolimus can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Temsirolimus.Approved, Illicit
ClofazimineThe serum concentration of Temsirolimus can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Temsirolimus.Approved, Investigational
ClomipramineThe serum concentration of Temsirolimus can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Temsirolimus.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Temsirolimus.Approved, Nutraceutical
ClotrimazoleThe metabolism of Temsirolimus can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clozapine.Approved
CobicistatThe metabolism of Temsirolimus can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Temsirolimus.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Temsirolimus.Approved
ColforsinThe serum concentration of Temsirolimus can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Temsirolimus can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Temsirolimus.Approved
CrizotinibThe metabolism of Temsirolimus can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Temsirolimus can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.Approved
DabrafenibThe serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Temsirolimus can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Temsirolimus can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Temsirolimus.Approved
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Temsirolimus.Approved
DasatinibThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Temsirolimus can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Temsirolimus.Approved
DeferasiroxThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Temsirolimus can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Temsirolimus.Investigational
DesipramineThe serum concentration of Temsirolimus can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temsirolimus.Approved
DesloratadineThe serum concentration of Temsirolimus can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Temsirolimus can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Temsirolimus can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Temsirolimus.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Temsirolimus can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Temsirolimus.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
DihydroergotamineThe metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Temsirolimus.Illicit
DiltiazemThe metabolism of Temsirolimus can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Temsirolimus can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Temsirolimus.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Temsirolimus can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Temsirolimus can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.Approved, Investigational
DoxorubicinThe serum concentration of Temsirolimus can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Temsirolimus can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Temsirolimus can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Temsirolimus can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Temsirolimus.Approved
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Temsirolimus.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Temsirolimus.Approved
EfavirenzThe serum concentration of Temsirolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Temsirolimus.Investigational
ElbasvirThe serum concentration of Temsirolimus can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Temsirolimus.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Temsirolimus.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus.Approved
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Temsirolimus.Experimental
EnzalutamideThe serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Temsirolimus.Approved, Investigational
ErgonovineThe serum concentration of Temsirolimus can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Temsirolimus can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Temsirolimus.Approved, Investigational
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Temsirolimus.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Temsirolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Temsirolimus.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Temsirolimus can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Temsirolimus can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Temsirolimus can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Temsirolimus.Approved
EtoposideThe serum concentration of Temsirolimus can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Temsirolimus can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Temsirolimus.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Temsirolimus.Approved
FelodipineThe serum concentration of Temsirolimus can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Temsirolimus can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.Approved
FexofenadineThe serum concentration of Temsirolimus can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Temsirolimus.Approved
FingolimodTemsirolimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Fluconazole.Approved
FluoxetineThe serum concentration of Temsirolimus can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Temsirolimus can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Temsirolimus can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Temsirolimus can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Temsirolimus.Approved
FluvoxamineThe metabolism of Temsirolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Temsirolimus.Approved
FosaprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Temsirolimus.Approved
FosphenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Temsirolimus is combined with G17DT.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Temsirolimus.Investigational
GefitinibThe serum concentration of Temsirolimus can be increased when it is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Temsirolimus.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Temsirolimus.Approved
GenisteinThe serum concentration of Temsirolimus can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Temsirolimus is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Temsirolimus.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Temsirolimus.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Temsirolimus.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Temsirolimus.Approved
GlyburideThe serum concentration of Temsirolimus can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Temsirolimus can be increased when it is combined with Glycerol.Experimental
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Temsirolimus.Experimental
Gramicidin DThe serum concentration of Temsirolimus can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Temsirolimus.Approved
GrepafloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Temsirolimus.Investigational
HaloperidolThe serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.Approved
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Temsirolimus.Experimental
HydrocortisoneThe serum concentration of Temsirolimus can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Temsirolimus.Approved
IdelalisibThe serum concentration of Temsirolimus can be increased when it is combined with Idelalisib.Approved
idraparinuxThe risk or severity of adverse effects can be increased when idraparinux is combined with Temsirolimus.Investigational
ImatinibThe metabolism of Temsirolimus can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Temsirolimus.Investigational
ImipramineThe serum concentration of Temsirolimus can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Temsirolimus.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Temsirolimus.Approved
IndomethacinThe serum concentration of Temsirolimus can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Temsirolimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Temsirolimus is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Temsirolimus.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Temsirolimus.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Temsirolimus.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Temsirolimus.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Temsirolimus.Approved, Investigational
IsavuconazoniumThe metabolism of Temsirolimus can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Temsirolimus.Approved, Withdrawn
IsradipineThe metabolism of Temsirolimus can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Temsirolimus can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Temsirolimus can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Temsirolimus.Approved
JosamycinThe risk or severity of adverse effects can be increased when Josamycin is combined with Temsirolimus.Approved
KetamineThe serum concentration of Temsirolimus can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Temsirolimus.Approved
KetoconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Temsirolimus can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Temsirolimus.Experimental
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Temsirolimus.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Temsirolimus.Approved, Investigational
LansoprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Temsirolimus can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Temsirolimus.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Temsirolimus.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Temsirolimus.Approved
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Temsirolimus.Approved, Investigational
LevofloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Temsirolimus.Approved
LevothyroxineThe serum concentration of Temsirolimus can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Temsirolimus can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temsirolimus.Approved
LiothyronineThe serum concentration of Temsirolimus can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Temsirolimus can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Temsirolimus.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.Approved, Investigational
LomitapideThe serum concentration of Temsirolimus can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Temsirolimus can be increased when it is combined with Loperamide.Approved
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Temsirolimus.Approved
LoratadineThe serum concentration of Temsirolimus can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Temsirolimus can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Temsirolimus can be decreased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Temsirolimus.Approved, Investigational
MaprotilineThe serum concentration of Temsirolimus can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Temsirolimus can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Temsirolimus can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Temsirolimus can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Temsirolimus can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temsirolimus.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.Approved
MethadoneThe serum concentration of Temsirolimus can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Temsirolimus.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Temsirolimus.Approved, Investigational
MibefradilThe serum concentration of Temsirolimus can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Temsirolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Temsirolimus.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Temsirolimus.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Temsirolimus.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
MitomycinThe serum concentration of Temsirolimus can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Temsirolimus can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Temsirolimus.Approved
MorphineThe serum concentration of Temsirolimus can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Temsirolimus.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Temsirolimus.Experimental
NadololThe serum concentration of Nadolol can be increased when it is combined with Temsirolimus.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temsirolimus.Investigational
NafcillinThe serum concentration of Temsirolimus can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Temsirolimus.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
NaltrexoneThe serum concentration of Temsirolimus can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Temsirolimus can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Temsirolimus.Investigational
NefazodoneThe metabolism of Temsirolimus can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus.Approved
NeostigmineThe serum concentration of Temsirolimus can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Temsirolimus can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Temsirolimus can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Temsirolimus can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Temsirolimus can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.Approved
NisoldipineThe serum concentration of Temsirolimus can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Temsirolimus can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Temsirolimus.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Temsirolimus.Approved
NorethisteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Temsirolimus.Approved, Investigational
OlaparibThe metabolism of Temsirolimus can be decreased when combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Temsirolimus.Vet Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Temsirolimus.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Temsirolimus.Approved
OmeprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Temsirolimus can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Temsirolimus.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Temsirolimus.Approved
P-NitrophenolThe serum concentration of Temsirolimus can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temsirolimus.Approved, Vet Approved
PalbociclibThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Temsirolimus.Approved, Investigational
PantoprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Temsirolimus can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.Approved
PentobarbitalThe metabolism of Temsirolimus can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Temsirolimus.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Temsirolimus.Approved, Withdrawn
PhenobarbitalThe metabolism of Temsirolimus can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Temsirolimus.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.Approved, Investigational
PimozideThe serum concentration of Temsirolimus can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Temsirolimus.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Temsirolimus.Approved
Platelet Activating FactorThe serum concentration of Temsirolimus can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Temsirolimus.Approved
PosaconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Temsirolimus.Approved, Investigational
PravastatinThe serum concentration of Temsirolimus can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Temsirolimus can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
PrednisoneThe serum concentration of Temsirolimus can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Temsirolimus can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Temsirolimus.Investigational
ProbenecidThe serum concentration of Temsirolimus can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Temsirolimus can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Temsirolimus can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Temsirolimus can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Temsirolimus can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Temsirolimus.Approved
QuercetinThe serum concentration of Temsirolimus can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Temsirolimus.Approved
QuinacrineThe serum concentration of Temsirolimus can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Temsirolimus.Approved, Investigational
QuinidineThe serum concentration of Temsirolimus can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Temsirolimus can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Temsirolimus.Approved
RacecadotrilThe risk or severity of adverse effects can be increased when Racecadotril is combined with Temsirolimus.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Temsirolimus.Approved
RanitidineThe serum concentration of Temsirolimus can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Temsirolimus.Approved, Investigational
ReboxetineThe serum concentration of Temsirolimus can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Temsirolimus can be increased when it is combined with Regorafenib.Approved
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Temsirolimus.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Temsirolimus can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Temsirolimus can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Temsirolimus.Approved, Investigational
RilpivirineThe serum concentration of Temsirolimus can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Temsirolimus.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Temsirolimus.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Temsirolimus.Approved
RolapitantThe serum concentration of Temsirolimus can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Temsirolimus.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Temsirolimus.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Temsirolimus.Approved, Vet Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Temsirolimus.Approved, Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temsirolimus.Approved
ScopolamineThe serum concentration of Temsirolimus can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Temsirolimus can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Temsirolimus.Approved
SertralineThe serum concentration of Temsirolimus can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Temsirolimus can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.Approved
SiltuximabThe serum concentration of Temsirolimus can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Temsirolimus.Approved
SimvastatinThe serum concentration of Temsirolimus can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temsirolimus.Approved
SirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temsirolimus.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Temsirolimus.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Temsirolimus.Investigational
SorafenibThe serum concentration of Temsirolimus can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Temsirolimus.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Temsirolimus.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Temsirolimus.Approved
SpironolactoneThe serum concentration of Temsirolimus can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Temsirolimus is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Temsirolimus can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Temsirolimus can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Temsirolimus can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Temsirolimus can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Temsirolimus can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Temsirolimus can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Temsirolimus.Approved, Investigational
SumatriptanThe serum concentration of Temsirolimus can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Temsirolimus can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.Approved, Investigational
TacrolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Temsirolimus can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Temsirolimus.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Temsirolimus.Approved
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Temsirolimus.Approved
TelmisartanThe serum concentration of Temsirolimus can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Temsirolimus.Experimental, Investigational
TerazosinThe serum concentration of Temsirolimus can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Temsirolimus can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Temsirolimus can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Temsirolimus can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Temsirolimus is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Temsirolimus.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Temsirolimus.Approved
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Temsirolimus.Experimental
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Temsirolimus.Approved
TiclopidineThe metabolism of Temsirolimus can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Temsirolimus.Approved
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.Approved, Investigational
TocilizumabThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTemsirolimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Temsirolimus.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Temsirolimus.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Temsirolimus.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Temsirolimus.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Temsirolimus.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Temsirolimus.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Temsirolimus.Approved
TrazodoneThe serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Temsirolimus can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Temsirolimus can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Temsirolimus can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Temsirolimus can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Temsirolimus.Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Troleandomycin is combined with Temsirolimus.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Temsirolimus.Vet Approved
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Temsirolimus.Experimental
UlinastatinThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Temsirolimus.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Temsirolimus.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Temsirolimus.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Temsirolimus.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Temsirolimus.Approved
VenlafaxineThe metabolism of Temsirolimus can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Temsirolimus can be decreased when combined with Verapamil.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temsirolimus.Approved, Investigational
VinblastineThe serum concentration of Temsirolimus can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.Approved, Investigational
VincristineThe serum concentration of Temsirolimus can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Temsirolimus can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Temsirolimus.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Temsirolimus.Approved, Investigational
VoriconazoleThe metabolism of Temsirolimus can be decreased when combined with Voriconazole.Approved, Investigational
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Temsirolimus.Approved, Investigational, Withdrawn
Ym150The risk or severity of adverse effects can be increased when Ym150 is combined with Temsirolimus.Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Temsirolimus.Approved
ZimelidineThe serum concentration of Temsirolimus can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Temsirolimus can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Kwang-Chung Lee, Ting-Huei Lee, Yen-Shih Tung, Chia-Chen Kao, Tzu-Ai Lee, “Process for preparation of temsirolimus.” U.S. Patent US20100249415, issued September 30, 2010.

US20100249415
General References
  1. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L: Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007 Nov;47(11):1430-9. Epub 2007 Oct 3. [PubMed:17913896 ]
External Links
ATC CodesL01XE09
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (402 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8908
Blood Brain Barrier-0.9494
Caco-2 permeable-0.664
P-glycoprotein substrateSubstrate0.8122
P-glycoprotein inhibitor IInhibitor0.8098
P-glycoprotein inhibitor IIInhibitor0.7467
Renal organic cation transporterNon-inhibitor0.7636
CYP450 2C9 substrateNon-substrate0.8699
CYP450 2D6 substrateNon-substrate0.8845
CYP450 3A4 substrateSubstrate0.7533
CYP450 1A2 substrateNon-inhibitor0.9126
CYP450 2C9 inhibitorNon-inhibitor0.8957
CYP450 2D6 inhibitorNon-inhibitor0.942
CYP450 2C19 inhibitorNon-inhibitor0.9155
CYP450 3A4 inhibitorNon-inhibitor0.9558
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9398
Ames testNon AMES toxic0.6087
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9522
Rat acute toxicity2.8760 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9703
hERG inhibition (predictor II)Non-inhibitor0.7479
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous25 mg
Injection, solution, concentrateIntravenous30 mg
Kit
LiquidIntravenous25 mg
Prices
Unit descriptionCostUnit
Torisel 25 mg kit1467.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2187024 No2004-08-102015-04-14Canada
CA2429020 No2009-05-262021-11-13Canada
US5362718 Yes1999-08-152019-08-15Us
US8026276 Yes2006-07-202026-07-20Us
US8299116 Yes2004-01-252024-01-25Us
US8455539 Yes2004-01-252024-01-25Us
US8722700 Yes2004-01-252024-01-25Us
US8791097 Yes2012-11-102032-11-10Us
USRE44768 Yes1999-08-152019-08-15Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00235 mg/mLALOGPS
logP4.39ALOGPS
logP7.13ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area241.96 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity277.07 m3·mol-1ChemAxon
Polarizability112.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Macrolide
  • Alpha-amino acid ester
  • Beta-hydroxy acid
  • Piperidine
  • Oxane
  • Hydroxy acid
  • Dicarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Cyclic ketone
  • Tertiary amine
  • Secondary alcohol
  • Lactone
  • Lactam
  • Ketone
  • Hemiacetal
  • Carboxylic acid ester
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Patard JJ, Pouessel D, Bensalah K, Culine S: Targeted therapy in renal cell carcinoma. World J Urol. 2008 Apr;26(2):135-40. doi: 10.1007/s00345-008-0237-4. Epub 2008 Feb 12. [PubMed:18265991 ]
  2. Radulovic S, Bjelogrlic SK: Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007 Sep;12 Suppl 1:S151-62. [PubMed:17935273 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:22 / Updated on December 03, 2016 04:02